Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.
Parkinson’s disease
clinical trials as topic
disease progression
outcome measures
Journal
Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
12
9
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
Identifying a meaningful progression metric for Parkinson's disease (PD) that reflects heterogeneity remains a challenge. To assess the frequency and baseline predictors of progression to clinically relevant motor and non-motor PD milestones. Using data from the Parkinson's Progression Markers Initiative (PPMI) de novo PD cohort, we monitored 25 milestones across six domains ("walking and balance"; "motor complications"; "cognition"; "autonomic dysfunction"; "functional dependence"; "activities of daily living"). Milestones were intended to be severe enough to reflect meaningful disability. We assessed the proportion of participants reaching any milestone; evaluated which occurred most frequently; and conducted a time-to-first-event analysis exploring whether baseline characteristics were associated with progression. Half of participants reached at least one milestone within five years. Milestones within the cognitive, functional dependence, and autonomic dysfunction domains were reached most often. Among participants who reached a milestone at an annual follow-up visit and remained active in the study, 82% continued to meet criteria for any milestone at one or more subsequent annual visits and 55% did so at the next annual visit. In multivariable analysis, baseline features predicting faster time to reaching a milestone included age (p < 0.0001), greater MDS-UPDRS total scores (p < 0.0001), higher GDS-15 depression scores (p = 0.0341), lower dopamine transporter binding (p = 0.0043), and lower CSF total α-synuclein levels (p = 0.0030). Symptomatic treatment was not significantly associated with reaching a milestone (p = 0.1639). Clinically relevant milestones occur frequently, even in early PD. Milestones were significantly associated with baseline clinical and biological markers, but not with symptomatic treatment. Further studies are necessary to validate these results, further assess the stability of milestones, and explore translating them into an outcome measure suitable for observational and therapeutic studies.
Sections du résumé
BACKGROUND
Identifying a meaningful progression metric for Parkinson's disease (PD) that reflects heterogeneity remains a challenge.
OBJECTIVE
To assess the frequency and baseline predictors of progression to clinically relevant motor and non-motor PD milestones.
METHODS
Using data from the Parkinson's Progression Markers Initiative (PPMI) de novo PD cohort, we monitored 25 milestones across six domains ("walking and balance"; "motor complications"; "cognition"; "autonomic dysfunction"; "functional dependence"; "activities of daily living"). Milestones were intended to be severe enough to reflect meaningful disability. We assessed the proportion of participants reaching any milestone; evaluated which occurred most frequently; and conducted a time-to-first-event analysis exploring whether baseline characteristics were associated with progression.
RESULTS
Half of participants reached at least one milestone within five years. Milestones within the cognitive, functional dependence, and autonomic dysfunction domains were reached most often. Among participants who reached a milestone at an annual follow-up visit and remained active in the study, 82% continued to meet criteria for any milestone at one or more subsequent annual visits and 55% did so at the next annual visit. In multivariable analysis, baseline features predicting faster time to reaching a milestone included age (p < 0.0001), greater MDS-UPDRS total scores (p < 0.0001), higher GDS-15 depression scores (p = 0.0341), lower dopamine transporter binding (p = 0.0043), and lower CSF total α-synuclein levels (p = 0.0030). Symptomatic treatment was not significantly associated with reaching a milestone (p = 0.1639).
CONCLUSION
Clinically relevant milestones occur frequently, even in early PD. Milestones were significantly associated with baseline clinical and biological markers, but not with symptomatic treatment. Further studies are necessary to validate these results, further assess the stability of milestones, and explore translating them into an outcome measure suitable for observational and therapeutic studies.
Identifiants
pubmed: 37458046
pii: JPD223433
doi: 10.3233/JPD-223433
pmc: PMC10578214
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
899-916Références
Brain. 2007 Jul;130(Pt 7):1787-98
pubmed: 17535834
Ann Clin Transl Neurol. 2020 Apr;7(4):449-461
pubmed: 32285645
Clin Auton Res. 2020 Jun;30(3):191-192
pubmed: 32361782
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Circulation. 2017 Jun 6;135(23):2299-2307
pubmed: 28584030
Stat Med. 1998 Jan 30;17(2):219-38
pubmed: 9483730
Parkinsonism Relat Disord. 2013 May;19(5):515-21
pubmed: 23462482
PLoS One. 2017 May 17;12(5):e0175674
pubmed: 28520803
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
Mov Disord. 2008 Apr 30;23(6):837-44
pubmed: 18307261
Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477
pubmed: 30564614
Mov Disord. 2013 May;28(5):668-70
pubmed: 23408503
Mov Disord. 2017 Aug;32(8):1117-1130
pubmed: 28734051
Ann Intern Med. 2020 May 5;172(9):591-598
pubmed: 32227247
Mov Disord. 2015 Jun;30(7):919-27
pubmed: 25737166
Ann Neurol. 2020 Sep;88(3):574-587
pubmed: 32542885
J Neurol. 1998 May;245 Suppl 1:S10-4
pubmed: 9617716
N Engl J Med. 1993 Jan 21;328(3):176-83
pubmed: 8417384
BMC Med Res Methodol. 2022 Feb 5;22(1):38
pubmed: 35123397
Mov Disord. 2020 May;35(5):833-844
pubmed: 32073681
J Neurol. 2020 Jan;267(1):214-227
pubmed: 31616991
J Clin Oncol. 2010 Dec 10;28(35):5132-9
pubmed: 21060033
Mov Disord. 2003 Jul;18(7):738-50
pubmed: 12815652
Mov Disord. 2019 Sep;34(9):1354-1364
pubmed: 31361367
JAMA. 2015 Feb 10;313(6):584-93
pubmed: 25668262
J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1258-64
pubmed: 23781007
Int J Epidemiol. 2015 Feb;44(1):324-33
pubmed: 25501468
Brain. 2010 Mar;133(Pt 3):713-26
pubmed: 20157014
Ann Clin Transl Neurol. 2021 Feb;8(2):308-320
pubmed: 33350601
JAMA Neurol. 2013 Oct;70(10):1277-87
pubmed: 23979011
J Neurol Sci. 2022 Jan 15;432:120082
pubmed: 34923333
Arch Neurol. 2005 Aug;62(8):1265-9
pubmed: 16087767
Neurology. 2002 Dec 10;59(11):1708-13
pubmed: 12473757
NPJ Parkinsons Dis. 2022 May 12;8(1):58
pubmed: 35550520
Neurosci Lett. 2013 Jan 4;532:44-8
pubmed: 23149132
Mov Disord. 2012 Oct;27(12):1513-21
pubmed: 23079770
JAMA Neurol. 2017 Aug 1;74(8):970-976
pubmed: 28655059
N Engl J Med. 2001 Sep 20;345(12):861-9
pubmed: 11565518
Mov Disord. 2009 Sep 15;24(12):1732-9
pubmed: 19514076
J Neurol. 2013 Jan;260(1):228-36
pubmed: 22865238
Neurology. 1990 Sep;40(9):1337-9
pubmed: 2118239
N Engl J Med. 1995 Dec 14;333(24):1581-7
pubmed: 7477192
Arch Neurol. 2003 Mar;60(3):387-92
pubmed: 12633150
JAMA. 2021 Sep 14;326(10):926-939
pubmed: 34519802
Am J Cardiol. 1993 Dec 16;72(19):3G-12G
pubmed: 8279357
Ann Clin Transl Neurol. 2016 May 17;3(7):482-94
pubmed: 27386498
Arch Neurol. 1995 Jun;52(6):565-70
pubmed: 7763203
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184
Mov Disord. 2009 Apr 30;24(6):813-8
pubmed: 19199355
Brain. 2004 Mar;127(Pt 3):550-60
pubmed: 14691062
Mov Disord. 2012 Sep 15;27(11):1392-7
pubmed: 22976926
Mov Disord. 2018 May;33(5):771-782
pubmed: 29572948
J Neurol. 2006 Dec;253 Suppl 7:VII2-6
pubmed: 17131223